Evidence map›Paper›PMID 34687063›Full record

ArticleAnnals of neurology2022

COVID-19 Vaccine Response in People with Multiple Sclerosis.

Emma C Tallantyre, Nicola Vickaryous, Valerie Anderson, Aliye Nazli Asardag, David Baker, Jonathan Bestwick, Kath Bramhall, Randy Chance, Nikos Evangelou, Katila George and 19 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of neurology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 89 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
89citing papers in PubMed, 5 pooled it
9.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

89 citing papers in PubMed, 5 syntheses or guidelines pooled it, 152 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Review
  7. Article
  8. Article
  9. Observational
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review

29 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors at 6 institutions in 2 countries.

Emma C Tallantyre *Division of Psychological Medicine and Clinical Neuroscience, School of Medicine, Cardiff University, Cardiff, UK.ORCID 0000-0002-3760-6634
Nicola Vickaryous *Preventive Neurology Unit, Wolfson Institute of Population Health, Queen Mary University London, London, UK.
Valerie AndersonDivision of Psychological Medicine and Clinical Neuroscience, School of Medicine, Cardiff University, Cardiff, UK.
Aliye Nazli AsardagBlizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
David BakerBlizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK.ORCID 0000-0002-8872-8711
Jonathan BestwickPreventive Neurology Unit, Wolfson Institute of Population Health, Queen Mary University London, London, UK.
Kath BramhallImmunodeficiency Centre for Wales, University Hospital of Wales, Cardiff, UK.
Randy ChanceBlizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
Nikos EvangelouDepartment of Clinical Neurology, University of Nottingham, Nottingham, UK.
Katila GeorgePreventive Neurology Unit, Wolfson Institute of Population Health, Queen Mary University London, London, UK.
Gavin GiovannoniPreventive Neurology Unit, Wolfson Institute of Population Health, Queen Mary University London, London, UK.
Andrew GodkinDivision of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, UK.
Leanne GrantImmunodeficiency Centre for Wales, University Hospital of Wales, Cardiff, UK.
Katharine E HardingDepartment of Neurology, Royal Gwent Hospital, Newport, UK.
Aimee HibbertDepartment of Clinical Neurology, University of Nottingham, Nottingham, UK.
Gillian IngramDepartment of Neurology, Morriston Hospital, Swansea, UK.
Meleri JonesBlizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
Angray S KangBlizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
Samantha LovelessDivision of Psychological Medicine and Clinical Neuroscience, School of Medicine, Cardiff University, Cardiff, UK.
Stuart J MoatWales Newborn Screening Laboratory, Department of Medical Biochemistry, Immunology and Toxicology, University Hospital of Wales, Cardiff, UK.
Neil P RobertsonDivision of Psychological Medicine and Clinical Neuroscience, School of Medicine, Cardiff University, Cardiff, UK.
Klaus SchmiererBlizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK.ORCID 0000-0002-9293-8893
Martin J ScurrDivision of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, UK.
Sita Navin ShahPreventive Neurology Unit, Wolfson Institute of Population Health, Queen Mary University London, London, UK.
Jessica SimmonsDivision of Psychological Medicine and Clinical Neuroscience, School of Medicine, Cardiff University, Cardiff, UK.
Matthew UpcottDivision of Psychological Medicine and Clinical Neuroscience, School of Medicine, Cardiff University, Cardiff, UK.
Mark WillisDepartment of Neurology, University Hospital of Wales, Cardiff, UK.
Stephen Jolles *Immunodeficiency Centre for Wales, University Hospital of Wales, Cardiff, UK.
Ruth Dobson *Preventive Neurology Unit, Wolfson Institute of Population Health, Queen Mary University London, London, UK.ORCID 0000-0002-2993-585X
Queen Mary University of London · GBUniversity Hospital of Wales · GBCardiff University · GBUniversity of Nottingham · GBMorriston Hospital · GBRoyal Gwent Hospital · GB

Funding

Medical Research Council MR/L010305/1
6 · The paper itself

Abstract

objectiveThe purpose of this study was to investigate the effect of disease modifying therapies on immune response to severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) vaccines in people with multiple sclerosis (MS).

methodsFour hundred seventy-three people with MS provided one or more dried blood spot samples. Information about coronavirus disease 2019 (COVID-19) and vaccine history, medical, and drug history were extracted from questionnaires and medical records. Dried blood spots were eluted and tested for antibodies to SARS-CoV-2. Antibody titers were partitioned into tertiles with people on no disease modifying therapy as a reference. We calculated the odds ratio of seroconversion (univariate logistic regression) and compared quantitative vaccine response (Kruskal Wallis) following the SARS-CoV-2 vaccine according to disease modifying therapy. We used regression modeling to explore the effect of vaccine timing, treatment duration, age, vaccine type, and lymphocyte count on vaccine response.

resultsCompared to no disease modifying therapy, the use of anti-CD20 monoclonal antibodies (odds ratio = 0.03, 95% confidence interval [CI] = 0.01-0.06, p < 0.001) and fingolimod (odds ratio = 0.04; 95% CI = 0.01-0.12) were associated with lower seroconversion following the SARS-CoV-2 vaccine. All other drugs did not differ significantly from the untreated cohort. Both time since last anti-CD20 treatment and total time on treatment were significantly associated with the response to the vaccination. The vaccine type significantly predicted seroconversion, but not in those on anti-CD20 medications. Preliminary data on cellular T-cell immunity showed 40% of seronegative subjects had measurable anti-SARS-CoV-2 T cell responses.

interpretationSome disease modifying therapies convey risk of attenuated serological response to SARS-CoV-2 vaccination in people with MS. We provide recommendations for the practical management of this patient group. ANN NEUROL 20219999:n/a-n/a.

Indexed as

Immunocompromised HostAdultAntibodies, ViralAntirheumatic AgentsCOVID-19COVID-19 VaccinesFemaleHumansMaleMiddle AgedMultiple SclerosisSARS-CoV-2SeroconversionUnited KingdomAntibodies, ViralAntirheumatic AgentsCOVID-19 Vaccines

Identifiers

PMID34687063
PMCPMC8652739
OpenAlexW3206641838

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.